Flinton Capital Management’s Enanta Pharmaceuticals ENTA Stock Holding History

Flinton Capital Management’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$94K	Buy	1,568 +128	+9%	+$9.51K	﹤0.01%	776
2019 Q2	$121K	Hold	1,440	–	–	﹤0.01%	756
2019 Q1	$138K	Hold	1,440	–	–	﹤0.01%	729
2018 Q4	$102K	Hold	1,440	–	–	﹤0.01%	748
2018 Q3	$123K	Buy	1,440 +448	+45%	+$44.9K	﹤0.01%	771
2018 Q2	$115K	Hold	992	–	–	﹤0.01%	744
2018 Q1	$80K	Buy	+992	New	+$76.3K	﹤0.01%	784
2017 Q1	–	Sell	-320	Closed	-$11K	–	851
2016 Q4	$11K	Buy	+320	New	+$9.17K	﹤0.01%	809

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Flinton Capital Management's ENTA Position: Q3 2019 in Review

Flinton Capital Management increased its Enanta Pharmaceuticals (ENTA) stake by 8.9% in Q3 2019, buying an estimated $9.51K and bringing the position to 1,568 shares worth $94K. The position accounts for ﹤0.01% of the portfolio, ranked #776.

Flinton Capital Management first reported a position in ENTA in Q4 2016 and has held it in 8 quarters since. The position peaked at $138K in Q1 2019. 176 funds tracked by Wall St. Rank hold ENTA as of Q3 2019.

Flinton Capital Management held 1,568 shares of Enanta Pharmaceuticals worth $94K as of Q3 2019.
Flinton Capital Management bought 128 Enanta Pharmaceuticals shares in Q3 2019, an estimated $9.51K.
Enanta Pharmaceuticals made up ﹤0.01% of Flinton Capital Management's portfolio in Q3 2019, its #776 holding.
Flinton Capital Management first reported a position in Enanta Pharmaceuticals in Q4 2016 and has held it in 8 quarters since.
Flinton Capital Management's Enanta Pharmaceuticals position peaked at $138K in Q1 2019.
176 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2019.

Based on Flinton Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.